Amarin Receives Special Protocol Assessment Agreement from the FDA ...WELT ONLINE, GermanyAmarin Corporation plc (NASDAQ:AMRN) today announced that it has reached agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned Phase 3 registration clinical trial of AMR101 (ethyl-EPA) in ...